Gossamer Bio, Inc. (GOSS)

Market Cap	157.57M
Revenue (ttm)	105.32M
Net Income (ttm)	-71.65M
Shares Out	226.23M
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,002,213
Open	0.710
Previous Close	0.715
Day's Range	0.681 - 0.720
52-Week Range	0.499 - 1.600
Beta	1.96
Analysts	Strong Buy
Price Target	9.20 (+1,220.89%)
Earnings Date	Nov 7, 2024

About GOSS

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The compa...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 8, 2019
• Employees: 135
• Stock Exchange: NASDAQ
• Ticker Symbol: GOSS
• Website: https://www.gossamerbio.com

Analyst Forecast

According to 5 analysts, the average rating for GOSS stock is "Strong Buy." The 12-month stock price forecast is $9.2, which is an increase of 1,220.89% from the latest price.

Price Target

$9.2

(1,220.89% upside)

Analyst Consensus: Strong Buy